Anavex Life Sciences Corp. Common Stock AVXL
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:55:02.466Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T22:23:33.313790318Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T02:55:01.705912+00:00
Anavex Life Sciences Corp. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | 1.04 | 321.8% | 39.6% | |||
| 35Δ | 1.16 | 309.2% | 35.8% | |||
| 40Δ | 1.27 | 296.6% | 32.0% | |||
| 45Δ | 1.39 | 284.0% | 28.2% | |||
| 50Δ | 1.50 | 271.4% | 24.4% | |||
| 55Δ | 1.47 | 241.4% | 61.1% | 1.62 | 258.8% | 20.6% |
| 60Δ | 1.25 | 216.6% | 42.0% | 1.73 | 246.2% | 16.8% |
| 65Δ | 1.03 | 191.7% | 22.9% | 1.85 | 233.6% | 13.0% |
| 70Δ | 1.96 | 221.0% | 9.3% | |||
| 75Δ | 2.44 | 238.0% | 7.0% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.04
- IV
- 321.8%
- B/E move
- 39.6%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.16
- IV
- 309.2%
- B/E move
- 35.8%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.27
- IV
- 296.6%
- B/E move
- 32.0%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.39
- IV
- 284.0%
- B/E move
- 28.2%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.50
- IV
- 271.4%
- B/E move
- 24.4%
55Δ
- Pseudo strike
- 1.47
- IV
- 241.4%
- B/E move
- 61.1%
- Pseudo strike
- 1.62
- IV
- 258.8%
- B/E move
- 20.6%
60Δ
- Pseudo strike
- 1.25
- IV
- 216.6%
- B/E move
- 42.0%
- Pseudo strike
- 1.73
- IV
- 246.2%
- B/E move
- 16.8%
65Δ
- Pseudo strike
- 1.03
- IV
- 191.7%
- B/E move
- 22.9%
- Pseudo strike
- 1.85
- IV
- 233.6%
- B/E move
- 13.0%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.96
- IV
- 221.0%
- B/E move
- 9.3%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.44
- IV
- 238.0%
- B/E move
- 7.0%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 224.29% | |
| 95.34% | |
| 96.72% | |
| 113.65% | |
| 169.24% | |
| 335.43% |
Biotechnology
AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is…
More →BBIO
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
More →BCAX
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. The company is headquartered in Boston, Massachusetts.
More →BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is…
More →BDTX
Description unavailable
More →BEAM
Description unavailable
More →